Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis

Introduction: Tocilizumab (TCZ) is an anti-interleukin-6 antibody that has been used for the treatment of severe coronavirus disease 2019 (COVID-19). However, concrete evidence of its benefit in reducing mortality in severe COVID-19 is lacking. Therefore, we performed a systematic review and meta-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Boregowda, Umesha, Perisetti, Abhilash, Nanjappa, Arpitha, Gajendran, Mahesh, Kutti Sridharan, Gurusaravanan, Goyal, Hemant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566918/
https://www.ncbi.nlm.nih.gov/pubmed/33123544
http://dx.doi.org/10.3389/fmed.2020.586221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566918/
https://www.ncbi.nlm.nih.gov/pubmed/33123544
http://dx.doi.org/10.3389/fmed.2020.586221

Ejemplares similares